Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(2.29)
# 2,547
Out of 4,847 analysts
131
Total ratings
38.79%
Success rate
-1.52%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Assumes: Overweight | $12 | $4.59 | +161.44% | 1 | May 27, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $9.97 | +150.75% | 3 | May 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $20 → $30 | $2.96 | +913.51% | 5 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $174.40 | +60.55% | 3 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $26.79 | +179.96% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $11.66 | +328.82% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $1.93 | +936.27% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $37.52 | +153.20% | 10 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $130.91 | +64.23% | 5 | Feb 20, 2025 | |
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $2.64 | +89.39% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $25.43 | +686.47% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $18.44 | +35.57% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.07 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $14.53 | +106.47% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.88 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.48 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $32.10 | +180.37% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.90 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $73.08 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.61 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.00 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.30 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $65.12 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.29 | +5,000.31% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $34.41 | +54.02% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $30.72 | +111.59% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $45.29 | +32.48% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $2.18 | +2,193.58% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $1.99 | +151.26% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.45 | +661.25% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $125.00 | +4.00% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $487.86 | +55.78% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $12.08 | +24.17% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $8.97 | +513.15% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.68 | +1,685.71% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.12 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $10.13 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $283.26 | -11.74% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $4.97 | +92,455.33% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $67.11 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $34.76 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.28 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $13.93 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $15.16 | +45.12% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.13 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $56.79 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $187.25 | -49.27% | 1 | Aug 17, 2017 | |
COMPASS Pathways
May 27, 2025
Assumes: Overweight
Price Target: $12
Current: $4.59
Upside: +161.44%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $9.97
Upside: +150.75%
Rocket Pharmaceuticals
May 16, 2025
Maintains: Overweight
Price Target: $20 → $30
Current: $2.96
Upside: +913.51%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $174.40
Upside: +60.55%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $26.79
Upside: +179.96%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $11.66
Upside: +328.82%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $1.93
Upside: +936.27%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $37.52
Upside: +153.20%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $130.91
Upside: +64.23%
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.64
Upside: +89.39%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $25.43
Upside: +686.47%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $18.44
Upside: +35.57%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.07
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $14.53
Upside: +106.47%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.88
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.48
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $32.10
Upside: +180.37%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.90
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $73.08
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.61
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.00
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.30
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $65.12
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.29
Upside: +5,000.31%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $34.41
Upside: +54.02%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $30.72
Upside: +111.59%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $45.29
Upside: +32.48%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.18
Upside: +2,193.58%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $1.99
Upside: +151.26%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.45
Upside: +661.25%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $125.00
Upside: +4.00%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $487.86
Upside: +55.78%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $12.08
Upside: +24.17%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $8.97
Upside: +513.15%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.68
Upside: +1,685.71%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.12
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $10.13
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $283.26
Upside: -11.74%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $4.97
Upside: +92,455.33%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $67.11
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $34.76
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.28
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $13.93
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $15.16
Upside: +45.12%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.13
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $56.79
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $187.25
Upside: -49.27%